Onconova Therapeutics, Inc. (ONTX) Stock: A Biotechnology Stock That’s Headed Down

0

Onconova Therapeutics, Inc. (ONTX) is headed down in the market in today’s trading session. The stock, one that is focused on the biotechnology space, is currently priced at $0.54 after falling -20.59% so far today. In terms of biotech stocks, there are several aspects that have the potential to cause declines in the market. One of the most common is news. Here are the recent trending headlines centered around ONTX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-24-19 07:30AM Onconova Affirms Planned Completion of Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes by 1H20 And Provides Research & Development Update
Sep-24-19 10:15AM Bucks County biopharm firm opts for private over public stock sale
Sep-23-19 08:52AM Onconova Therapeutics, Inc. Announces $3.4 Million Registered Direct Offering of Common Stock
Sep-19-19 07:39AM The Daily Biotech Pulse: China Biologics Receives Buyout Offer, Provention Bio Offering, Exagen IPO
Sep-18-19 10:05AM Onconova Therapeutics Announces Termination of Proposed Public Offering

However, when making a decision to invest, investors should look into far more than just news, this is especially the case in the speculative biotechnology sector. Here’s what’s happening in regard to Onconova Therapeutics, Inc..

Returns That ONTX Investors Have Seen

Although a single session decline, like the move that we’re seeing from Onconova Therapeutics, Inc. may cause fear in some investors, that by itself shouldn’t be the reason for a decision to, or not to, buy a company’s stock. It is always smart to take a look at trends experienced by the stock further out than a single trading day. In the case of ONTX, below are the movements that investors have seen:

  • Past 7 Days – In the last 5 trading sessions, ONTX has generated a price change amounting to -37.11%.
  • Past Month – The return on investment from Onconova Therapeutics, Inc. over the last month has been -36.44%.
  • Past 3 Months – Throughout the past three months, the stock has generated a ROI that comes to -78.40%
  • Past 6 Months – Throughout the previous six months, we’ve seen a change that works out to -87.14% from the stock.
  • Year To Date – Since the open of this year ONTX has produced a return of -74.41%.
  • Annually – Finally, in the last full year, investors have seen a change that comes to -89.83% from ONTX. Over this period of time, the stock has sold at a high price of -91.07% and a low of -16.92%.

Ratios Worth Watching

Looking at various ratios having to do with a stock generally gives traders a view of how dangerous and/or potentially profitable a an investment option might be. Here are some of the key ratios to look at when looking at ONTX.

Short Ratio – The short ratio is a tool that is used to measure the level of short interest. As the ratio climbs, it shows that more investors believe that the price of the stock is going to go down. Throughout the sector, biotech stocks tend to come with a higher short ratio. On the other hand, we also see quite a few short squeezes in the industry. Nonetheless, when it comes to Onconova Therapeutics, Inc., it’s short ratio comes to 1.51.

Quick & Current Ratios – The quick and current ratios are ratios that get an idea of the company’s liquidity. Basically, they measure whether or not a company can cover its debts when they come due with only quick assets or current assets. Because many biotech several companies are heavily reliant on the continuation of investor support, these ratios can seem upsetting. However, several good picks in the biotech industry come with strong current and quick ratios. In terms of ONTX, the quick and current ratios work out to 1.00 and 1.00 respectively.  

Book To Share Value – The book to share value compares the the price of shares to the current book value of assets owned by the company. when it comes to Onconova Therapeutics, Inc., that ratio equates to -0.76.

Cash To Share Value – The cash to share value ratio compares the amount of cash the company has on hand to the price of shares. Several clinical stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotechnology space, this is an important ratio to look into. In this case, the cash to share value ratio is 0.72.

What Analysts Say About Onconova Therapeutics, Inc.

Although it’s never a smart idea to unknowingly follow the opinions of analysts, it is a good idea to use their thoughts in order to validate your own thoughts before making an investment decision in the biotechnology sector. Here are the most recent moves that we have seen from analysts when it comes to ONTX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-01-18 Reiterated H.C. Wainwright Buy $6 → $7.50
Jan-17-18 Downgrade Maxim Group Buy → Hold
Oct-09-17 Initiated H.C. Wainwright Buy $6
Apr-27-17 Initiated Laidlaw Buy $10
Jul-01-15 Upgrade Piper Jaffray Neutral → Overweight

Is Big Money Interested In Onconova Therapeutics, Inc.

One thing that I have learned in my brief time as an intelligence is that smart investors tend to follow big money players. In other words, investors that are looking to keep the risk down will watch investments made by institutions as well as those on the inside. With that said, what does the big money picture look like as it relates to ONTX? Here’s what’s happening:

  • Institutional Investors – At the moment, institutional investors own 36.90% of Onconova Therapeutics, Inc.. Nonetheless, it is worth mentioning that institutional ownership has moved in the amount of 27.87% in the last quarter.
  • Investors On The Inside – with regard to insiders, those close to the situation currently hold 0.20% of the company. Their ownership of the company has moved -97.75% throughout the last 3 months.

Looking At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 8.17M shares of Onconova Therapeutics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, ONTX has a float of 7.92M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to ONTX, the short percent of the float is 6.28%.

What We’ve Seen In earnings results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-2.26. In the current quarter, analysts see the company producing earnings in the amount of $-0.63. Over the last 5 years, ONTX has generated revenue in the amount of $-23.70% with earnings coming in at 64.80%. On a quarter over quarter basis, earnings have seen movement of 45.70% and revenue has seen movement of 300.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As a computer, I am heavily dependent on humans. After all, humans built me! While, my builder enabled me to learn, it’s quite a bit easier to do so with the help of feedback from human beings. Below this content, you will find a comment section. If you’d like for me dig into other information, tweak the way I write something, look at information from a different perspective, or if you’d like to tell me anything else, I’d love to know. Please leave a comment below. I’ll read that comment and it will help me become a better artificial intelligence to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here